2.要約四半期連結財務諸表及び主な注記

(1)要約四半期連結財政状態計算書

 

 

 

 

 

(単位:百万円)

 

 

 

前連結会計年度末

(2025年3月31日)

 

当第1四半期連結会計期間

(2025年6月30日)

資産

 

 

 

 

 

流動資産

 

 

 

 

 

現金及び現金同等物

 

 

55,241

 

58,277

営業債権及びその他の債権

 

 

42,292

 

42,452

棚卸資産

 

 

42,500

 

45,700

その他の金融資産

 

 

3,244

 

3,654

その他の流動資産

 

 

6,461

 

7,583

流動資産合計

 

 

149,740

 

157,667

非流動資産

 

 

 

 

 

有形固定資産

 

 

34,531

 

34,391

無形資産

 

 

48,315

 

47,749

使用権資産

 

 

2,781

 

2,474

その他の金融資産

 

 

39,492

 

37,512

繰延税金資産

 

 

5,597

 

6,642

その他の非流動資産

 

 

3,177

 

3,186

非流動資産合計

 

 

133,897

 

131,957

資産合計

 

 

283,637

 

289,625

 

 

 

 

 

 

 

 

 

 

 

 

 

(単位:百万円)

 

 

 

前連結会計年度末

(2025年3月31日)

 

当第1四半期連結会計期間

(2025年6月30日)

負債及び資本

 

 

 

 

 

負債

 

 

 

 

 

流動負債

 

 

 

 

 

営業債務及びその他の債務

 

 

16,857

 

18,192

その他の金融負債

 

 

305

 

299

リース負債

 

 

1,348

 

1,224

未払法人所得税

 

 

4,705

 

3,451

その他の流動負債

 

 

7,100

 

8,796

流動負債合計

 

 

30,316

 

31,964

非流動負債

 

 

 

 

 

その他の金融負債

 

 

233

 

233

リース負債

 

 

1,374

 

1,197

退職給付に係る負債

 

 

4,313

 

4,336

その他の非流動負債

 

 

59

 

59

非流動負債合計

 

 

5,980

 

5,826

負債合計

 

 

36,297

 

37,791

資本

 

 

 

 

 

資本金

 

 

5,174

 

5,174

資本剰余金

 

 

4,491

 

4,514

利益剰余金

 

 

222,640

 

228,538

自己株式

 

 

2,459

 

2,459

その他の資本の構成要素

 

 

17,181

 

15,754

親会社の所有者に帰属する持分合計

 

 

247,028

 

251,521

非支配持分

 

 

312

 

312

資本合計

 

 

247,340

 

251,834

負債及び資本合計

 

 

283,637

 

289,625

 

E0093145160日本新薬株式会社Nippon Shinyaku Co.,Ltd.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2025-04-012025-06-30Q12026-03-312024-04-012024-06-302025-03-311falsefalsefalse451602024-03-31451602025-03-31451602024-04-012024-06-30451602024-06-30451602025-04-012025-06-30451602025-06-30451602025-08-07451602024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-03-31jpigp_cor:ShareCapitalIFRSMember451602024-03-31jpigp_cor:CapitalSurplusIFRSMember451602024-03-31jpigp_cor:RetainedEarningsIFRSMember451602024-03-31jpigp_cor:TreasurySharesIFRSMember451602024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-03-31jpigp_cor:NonControllingInterestsIFRSMember451602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpigp_cor:CapitalSurplusIFRSMember451602025-03-31jpigp_cor:RetainedEarningsIFRSMember451602025-03-31jpigp_cor:TreasurySharesIFRSMember451602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602024-04-012024-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-04-012024-06-30jpigp_cor:ShareCapitalIFRSMember451602024-04-012024-06-30jpigp_cor:CapitalSurplusIFRSMember451602024-04-012024-06-30jpigp_cor:RetainedEarningsIFRSMember451602024-04-012024-06-30jpigp_cor:TreasurySharesIFRSMember451602024-04-012024-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-04-012024-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-04-012024-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-04-012024-06-30jpigp_cor:NonControllingInterestsIFRSMember451602024-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-06-30jpigp_cor:ShareCapitalIFRSMember451602024-06-30jpigp_cor:CapitalSurplusIFRSMember451602024-06-30jpigp_cor:RetainedEarningsIFRSMember451602024-06-30jpigp_cor:TreasurySharesIFRSMember451602024-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-06-30jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-04-012025-06-30jpigp_cor:ShareCapitalIFRSMember451602025-04-012025-06-30jpigp_cor:CapitalSurplusIFRSMember451602025-04-012025-06-30jpigp_cor:RetainedEarningsIFRSMember451602025-04-012025-06-30jpigp_cor:TreasurySharesIFRSMember451602025-04-012025-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-04-012025-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-04-012025-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-04-012025-06-30jpigp_cor:NonControllingInterestsIFRSMember451602025-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-06-30jpigp_cor:ShareCapitalIFRSMember451602025-06-30jpigp_cor:CapitalSurplusIFRSMember451602025-06-30jpigp_cor:RetainedEarningsIFRSMember451602025-06-30jpigp_cor:TreasurySharesIFRSMember451602025-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-06-30jpigp_cor:NonControllingInterestsIFRSMember451602024-04-012024-06-30jpcrp_cor:ReportableSegmentsMember451602024-04-012024-06-30tse-qcediffr-45160:MedicineReportableSegmentMember451602024-04-012024-06-30tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602024-04-012024-06-30jpcrp_cor:ReconcilingItemsMember451602025-04-012025-06-30jpcrp_cor:ReportableSegmentsMember451602025-04-012025-06-30tse-qcediffr-45160:MedicineReportableSegmentMember451602025-04-012025-06-30tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602025-04-012025-06-30jpcrp_cor:ReconcilingItemsMemberxbrli:pureiso4217:JPYxbrli:sharesiso4217:JPY